Paul A. Hamlin

Phase II Clinical Experience With the Novel Proteasome Inhibitor Bortezomib in Patients With Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma

Owen A. O’Connor, Craig H. Moskowitz, Jamie Muzzy et al. · Journal of Clinical Oncology · 2004 · 579 citations

Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma

Christian Grommes, Alessandro Pastore, Nicolaos Palaskas et al. · Cancer Discovery · 2017 · 390 citations · Full text

Risk-Adapted Dose-Dense Immunochemotherapy Determined by Interim FDG-PET in Advanced-Stage Diffuse Large B-Cell Lymphoma

Craig H. Moskowitz, Heiko Schöder, Julie Teruya‐Feldstein et al. · Journal of Clinical Oncology · 2010 · 324 citations · Full text

Progression-free Survival, Immunology, Pathology +18

Normalization of pre-ASCT, FDG-PET imaging with second-line, non–cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma

Craig H. Moskowitz, Matthew J. Matasar, Andrew D. Zelenetz et al. · Blood · 2011 · 280 citations · Full text

PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study

Alison J. Moskowitz, Heiko Schöder, Joachim Yahalom et al. · The Lancet Oncology · 2015 · 263 citations

Lymphoid Neoplasia, Refractory Hodgkin, Augmented Ifosamide +10